42437069 2025-01-01 2025-12-31 2 42437069 2025-01-01 2025-12-31 42437069 2025-01-01 2025-12-31 1 42437069 2025-01-01 2025-12-31 1 42437069 2024-01-01 2024-12-31 42437069 2025-12-31 42437069 2024-12-31 42437069 2025-01-01 d:ContributedCapitalMember 42437069 2025-01-01 d:RetainedEarningsMember 42437069 2025-01-01 2025-12-31 d:RetainedEarningsMember 42437069 2025-12-31 d:ContributedCapitalMember 42437069 2025-12-31 d:RetainedEarningsMember 42437069 2025-01-01 d:ConvertibleProfitYieldingOrDividendYieldingLongtermDebtInstrumentsMember 42437069 2025-12-31 d:ConvertibleProfitYieldingOrDividendYieldingLongtermDebtInstrumentsMember 42437069 2025-01-01 d:LongtermPayablesToGroupEnterprisesMember 42437069 2025-12-31 d:LongtermPayablesToGroupEnterprisesMember xbrli:pure iso4217:DKK 33256876 33256876 false Crowe 2900 Hellerup Crowe Regnskabsklasse B Rygårds Allé 104 2025-01-01 2025-12-31 Dayanand Suryabhan Jadhav 2024-01-01 2024-12-31 true 2026-05-11 Andre erklæringer uden sikkerhed CaseWare-FSR Annual report 5 The executive board has today discussed and approved the annual report of G2B BioSolutions ApS for the financial year 1 January - 31 December 2025. The annual report is prepared in accordance with the Danish Financial Statements Act. In my opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2025 and of the results of the company's operations for the financial year 1 January - 31 December 2025. In my opinion, management's review includes a fair review of the matters dealt with in the management's review. The financial statements have not been audited. Management considers the criteria for not auditing the financial statements to be met. Management recommends that the annual report should be approved by the company in general meeting. Dayanand Suryabhan Jadhav Director To the shareholder of G2B BioSolutions ApS We have compiled the financial statements of G2B BioSolutions ApS for the financial year 1 January - 31 December 2025 based on the company's bookkeeping records and other information made available by enterprise.The financial statements comprises a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes.We performed the engagement in accordance with ISRS 4410, Compilation Engagements.We have applied our professional expertise to assist the enterprise in the preparation and presentation of the financial statements in accordance with the Danish Financial Statements Act. We complied with the relevant provisions of the Danish Act on Approved Auditors and with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), including principles relating to integrity, objectivity, professional competence and due care.The financial statements and the accuracy and completeness of the information used to compile the financial statements are the enterprise´s responsibility.As a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information provided by enterprise for our compilation of the financial statements. Accordingly, we do not express an audit or a review conclusion on whether the financial statements have been prepared in accordance with the Danish Financial Statements Act. Hellerup 2026-05-11 Jamal Naveed Broholt Janjooa State Authorized Public Accountant mne49080 Søren Jonassen State Authorized Public Accountant mne18488 G2B BioSolutions ApS Hagens Alle  7 2900  Hellerup 42437069 Gentofte Crowe 33256876 Rygårds Allé 104 2900 Hellerup Business reviewThe company's purpose is to conduct business with trade, service, production and thus, at the management's discretion, related business. Financial review The company's income statement for the year ended 31. december 2025 shows a profit of DKK 136.864, and the balance sheet at 31 December 2025 shows negative equity of DKK 1.213.372.Uncertainty about the continued operation (going concern)The company has lost its entire share capital, which is in line with management’s expectations.   It is expected that the share capital will be re-established through operations once the development project has been completed.   The company is financially supported by the company’s ultimate owner, who has issued a letter of support valid until the date of approval of the annual report for the financial year ended 31 December 2026.   On this basis, management considers that the annual report may be prepared on a going concern basis.   Reference is made to Note 1 "Uncertainty related to going concern". Significant events occurring after the end of the financial yearNo events have occurred after the balance sheet date which could significantly affect the company's financial position. The annual report of G2B BioSolutions ApS for 2025 has been prepared in accordance with the provisions of the Danish Financial Statements Act ap­plying to en­ter­pri­ses of re­por­ting class B, as well as provisions applying to reporting class C entities.The accounting policies applied are consistent with those of last year.The annual report for 2025 is pre­sen­ted in DKK Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement.Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably.Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company and the value of the liability can be measured reliably.On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item.Certain financial assets and liabilities are measured at amortised cost using the effective interest method. Amortised cost is calculated as the historic cost less any installments and plus/less the accumulated amortisation of the difference between the cost and the nominal amount.On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date. In pursuance of section 32 of the Danish Financial Statements Act, the company does not disclose its revenue. Gross profit reflects an aggregation of other operating income less cost of raw materials and consumables and other external expenses. Costs of raw materials and consumables include the raw materials and consumables used in generating the year’s revenue. The item Other operating income includes items of a secondary nature relative to the company’s activities, including gains on the sale of intangible assets and items of property, plant and equipment, operating losses, indemnities relating to operating losses and conflicts as well as payroll refunds. Indemnities are recognised when it is more probable than not that the company is going to be indemnified. Other external expenses include expenses related to sale, advertising, administration, premises etc. Staff costs include wages and salaries, including compensated absence and pensions, as well as other social security contributions, etc. made to the entity's employees. Financial income and expenses are recognised in the income statement at the amounts that relate to the financial year. Net financials include interest income and expenses, liabilities and foreign currency transactions, and surcharges and allowances under the Danish Tax Prepayment Scheme, etc. The company is subject to the Danish rules on compulsory joint taxation of the Group's Danish subsidiaries. Subsidiaries participate in the joint taxation arrangement from the time when they are included in the consolidated financial statements and until the time when they withdraw from the consolidation.The company is subject to the Danish rules on compulsory joint taxation.On payment of joint taxation contributions, the current Danish income tax is allocated between the jointly taxed entities in proportion to their taxable income. Entities with tax losses receive joint taxation contributions from entities that have been able to use tax losses to reduce their own taxable profits.Tax for the year, which comprises the current tax charge for the year and changes in the deferred tax charge, is recognised in the income statement as regards the portion that relates to the profit/loss for the year and directly in equity as regards the portion that relates to entries directly in equity. PatentsPatents are measured at cost less accumulated amortisation and impairment losses. Patents are amortised on a straight-line basis over the remaining patent period however not more than 8 years.Gains and losses on the disposal of patents are determined as the difference between the selling price less costs to sell and the carrying amount at the date of disposal. Gains or losses are recognised in the income statement as other operating income or other operating expenses, respectively. Investment in subsidiaries are measured at cost. If cost exceeds the recoverable amount, a write-down is made to this lower value. Receivables are measured at amortised cost.An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable is impaired, an impairment loss for that individual asset is recognised.Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received, using the effective interest rate of individual receivables or portfolios of receivables as discount rate. Cash and cash equivalents deposits at banks. DividendsProposed dividends are disclosed as a separate item under equity. Dividends are recognised as a liability when declared by the annual general meeting of shareholders. Current tax liabilities and current tax receivables are recognised in the balance sheet as the estimated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and tax paid on account.The company and all its Danish group entities are taxed on a joint basis. The current income tax charge is allocated between the jointly taxed entities relative to their taxable income. Tax losses are allocated based on the full absorption method. The jointly taxed entities are eligible for the Danish Tax Prepayment Scheme.Deferred tax is measured according to the liability method in respect of temporary differences between the carrying amount of assets and liabilities and their tax base, calculated on the basis of the planned use of the asset and settlement of the liability, respectively. Deferred tax is measured at net realisable value.Deferred tax assets, including the tax base of tax losses allowed for carry forward, are measured at the value to which the asset is expected to be realised, either as a set-off against tax on future income or as a set-off against deferred tax liabilities within the same legal tax entity. Any deferred net tax assets are measured at net realisable value. Liabilities, which include trade payables and other payables, are measured at amortised cost, which is usually equivalent to nominal value. On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or financial expenses. If foreign currency instruments are considered cash flow hedges, any unrealised value adjustments are taken directly to a fair value reserve under ‘Equity’. 44817 435674 0 54411 36291 0 8526 381263 39003 10523 -30477 370740 -167341 0 136864 370740 136864 370740 343235 262745 343235 262745 0 40000 0 40000 343235 302745 203461 31730 203461 31730 88073 257425 291534 289155 634769 591900 40000 40000 -1253372 -1390236 -1213372 -1350236 530000 500000 186617 305617 716617 805617 55125 15000 0 85120 1076399 1036399 1131524 1136519 1848141 1942136 634769 591900 40000 -1390236 136864 40000 -1253372 The company has lost its entire share capital, which is in line with management’s expectations.   It is expected that the share capital will be re-established through operations once the development project has been completed.   The company is financially supported by the company’s ultimate owner, who has issued a letter of support valid until the date of approval of the annual report for the financial year ended 31 December 2026.   On this basis, management considers that the annual report may be prepared on a going concern basis. 0 52758 0 1653 0 54411 0 1 6000 5617 33003 4906 39003 10523 -167341 0 Investments in subsidaries are specified as follows: 500000 530000 0 0 305617 186617 0 0 The company is jointly taxed with its parent company, Dayanad Jadhav Holding ApS (management company), and jointly and severally liable with other jointly taxed entities for payment of income taxes as well as for payment of withholding taxes on dividends which fall due for payment on. None.